Oral Leukoplakia clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Pembrolizumab in Treating Participants With Leukoplakia
open to eligible people ages 18 years and up
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
at UCLA UCSD
Our lead scientists for Oral Leukoplakia research studies include Deborah Wong.